Li Feng, Li Hao, Luo Rong, Pei Jia-Bao, Yu Xue-Ying
Department of Cardiovascular Internal Medicine, People's Hospital of Jieshou, Jieshou 236500, Anhui Province, China.
World J Clin Cases. 2023 Sep 16;11(26):6066-6072. doi: 10.12998/wjcc.v11.i26.6066.
Chronic heart failure (CHF) is a serious and prevalent condition characterized by impaired cardiac function and inflammation. Standard therapy for CHF has limitations, prompting the exploration of alternative treatments. Recombinant human brain natriuretic peptide (BNP) has emerged as a potential therapy, with evidence suggesting that it can improve cardiac function and reduce inflammation in patients with CHF. However, further research is required to determine the efficacy and safety of lyophilized recombinant human BNP in CHF patients and its impact on microinflammatory status. This study aimed to investigate the effects of lyophilized recombinant human BNP therapy on CHF patients' cardiac function and microinflammatory status.
To investigate the effects of freeze-dried recombinant human BNP therapy on cardiac function and microinflammatory status in patients with CHF.
In total, 102 CHF patients admitted to our hospital from January 2021 to January 2022 were randomly assigned to control and observation groups ( = 51 patients/group). The control patients were treated with standard HF therapy for 3 d, whereas the observational patients were injected with the recombinant human BNP for 3 d. Clinical efficacy, inflammatory factor levels, myocardial damage, cardiac function before and after the treatment, and adverse reactions during treatment were compared between the two groups.
The overall clinical efficacy was higher in the observation group than in the control group. Compared with baseline, serum hypersensitive C-reactive protein, N-terminal proBNP, and troponin I level, and physical, emotional, social, and economic scores were lower in both groups after treatment, with greater reductions in levels and scores noted in the observation group than in the control group. The overall incidence of adverse reactions in the observation group was not significantly different compared with that in the control group ( > 0.05).
Freeze-dried recombinant human BNP therapy can improve heart function and enhance microinflammatory status, thereby improving overall quality of life without any obvious side effects. This therapy is safe and reliable.
慢性心力衰竭（CHF）是一种严重且普遍的病症，其特征为心功能受损和炎症反应。CHF的标准治疗存在局限性，这促使人们探索替代治疗方法。重组人脑钠肽（BNP）已成为一种潜在的治疗方法，有证据表明它可以改善CHF患者的心功能并减轻炎症。然而，需要进一步研究以确定冻干重组人BNP在CHF患者中的疗效和安全性及其对微炎症状态的影响。本研究旨在探讨冻干重组人BNP治疗对CHF患者心功能和微炎症状态的影响。
探讨冻干重组人BNP治疗对CHF患者心功能和微炎症状态的影响。
选取2021年1月至2022年1月我院收治的102例CHF患者，随机分为对照组和观察组（每组51例）。对照组患者接受标准心力衰竭治疗3天，而观察组患者注射重组人BNP 3天。比较两组的临床疗效、炎症因子水平、心肌损伤、治疗前后的心功能以及治疗期间的不良反应。
观察组的总体临床疗效高于对照组。与基线相比，两组治疗后血清超敏C反应蛋白、N末端脑钠肽前体和肌钙蛋白I水平以及生理、情感、社会和经济评分均降低，且观察组的水平和评分降低幅度大于对照组。观察组不良反应的总体发生率与对照组相比无显著差异（P>0.05）。
冻干重组人BNP治疗可改善心功能，增强微炎症状态，从而提高总体生活质量，且无明显副作用。该治疗安全可靠。
